Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Preferred Stock Liabilities (2017 - 2018)

Historic Preferred Stock Liabilities for Sutro Biopharma (STRO) over the last 2 years, with Q3 2018 value amounting to $187.2 million.

  • Sutro Biopharma's Preferred Stock Liabilities changed N/A to $187.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $187.2 million, marking a year-over-year change of. This contributed to the annual value of $102.5 million for FY2017, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2018, Sutro Biopharma's Preferred Stock Liabilities is $187.2 million.
  • Over the past 5 years, Sutro Biopharma's Preferred Stock Liabilities peaked at $187.2 million during Q3 2018, and registered a low of $102.5 million during Q4 2017.